Haloxon

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592208

CAS#: 321-55-1

Description: Haloxon is a Peripheral site ligand that accelerates inhibition of acetylcholinesterase.

Chemical Structure

img
Haloxon
CAS# 321-55-1
Instruction

Theoretical Analysis

MedKoo Cat#: 592208
Name: Haloxon
CAS#: 321-55-1
Chemical Formula: C14H14Cl3Cl3O6P
Exact Mass: 413.96
Molecular Weight: 413.580
Elemental Analysis: C, 40.46; H, 3.40; Cl, 25.59; O, 23.10; P, 7.45

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Haloxon

IUPAC/Chemical Name: 3-Chloro-7-hydroxy-4-methylcoumarin bis(2-chloroethyl)phosphate

InChi Key: KULDXINYXFTXMO-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H14Cl3O6P/c1-9-11-3-2-10(8-12(11)22-14(18)13(9)17)23-24(19,20-6-4-15)21-7-5-16/h2-3,8H,4-7H2,1H3

SMILES Code: O=C1OC2=C(C=CC(OP(OCCCl)(OCCCl)=O)=C2)C(C)=C1Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 413.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sinko G, Bosak A, Kovarik Z, Simeon-Rudolf V. Structure-inhibition relationships in the interaction of butyrylcholinesterase with bambuterol, haloxon and their leaving groups. Chem Biol Interact. 2005 Dec 15;157-158:421-3. PubMed PMID: 16429568.

2: Radić Z, Taylor P. Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates. J Appl Toxicol. 2001 Dec;21 Suppl 1:S13-4. PubMed PMID: 11920914.

3: Radić Z, Taylor P. The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact. 1999 May 14;119-120:111-7. PubMed PMID: 10421444.

4: Martin RJ. Modes of action of anthelmintic drugs. Vet J. 1997 Jul;154(1):11-34. Review. PubMed PMID: 9265850.

5: Schmuck G, Ahr HJ. Improved in vitro method for screening organophosphate-induced delayed polyneuropathy. Toxicol In Vitro. 1997 Jun;11(3):263-70. PubMed PMID: 20654312.

6: Nagayama M, Akahori F, Chiwata H, Shirai M, Motoya M, Masaoka T, Sakaguchi K. Effects of selected organophosphate insecticides on serum cholinesterase isoenzyme patterns in the rat. Vet Hum Toxicol. 1996 Jun;38(3):196-9. PubMed PMID: 8727219.

7: Bourke CA. The clinical differentiation of nervous and muscular locomotor disorders of sheep in Australia. Aust Vet J. 1995 Jun;72(6):228-34. Review. PubMed PMID: 8526819.

8: Bohuslavizki KH, Hänsel W, Kneip A, Koppenhöfer E, Niemöller E, Sanmann K. Mode of action of psoralens, benzofurans, acridinons, and coumarins on the ionic currents in intact myelinated nerve fibres and its significance in demyelinating diseases. Gen Physiol Biophys. 1994 Aug;13(4):309-28. PubMed PMID: 7890147.

9: Zahner H, Schares G. Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi. Acta Trop. 1993 Jan;52(4):221-66. Review. PubMed PMID: 8094587.

10: Radić Z, Reiner E, Taylor P. Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. Mol Pharmacol. 1991 Jan;39(1):98-104. PubMed PMID: 1987454.

11: Sharma RK, Singh K, Saxena KK. Effect of cambendazole and haloxon on the carbohydrate metabolism of Ascaridia galli and Heterakis gallinae (Nematoda). Angew Parasitol. 1990 May;31(2):101-5. PubMed PMID: 2389827.

12: Prichard RK. Anthelmintics and control. Vet Parasitol. 1988 Feb;27(1-2):97-109. Review. PubMed PMID: 3284172.

13: Sharma RK, Singh K, Saxena R, Saxena KK. Effect of some anthelmintics on malate dehydrogenase activity and mortality in two avian nematodes Ascaridia galli and Heterakis gallinae. Angew Parasitol. 1986 Aug;27(3):175-80. PubMed PMID: 3777528.

14: Prichard RK. Anthelmintics for cattle. Vet Clin North Am Food Anim Pract. 1986 Jul;2(2):489-501. PubMed PMID: 3488116.

15: Rew RS, Urban JF Jr, Douvres FW. Screen for anthelmintics, using larvae of Ascaris suum. Am J Vet Res. 1986 Apr;47(4):869-73. PubMed PMID: 3963590.

16: Radić Z, Reiner E, Simeon V. Binding sites on acetylcholinesterase for reversible ligands and phosphorylating agents. A theoretical model tested on haloxon and phosphostigmine. Biochem Pharmacol. 1984 Feb 15;33(4):671-7. PubMed PMID: 6704184.

17: Zahner H, Weidner E. Occurrence of microfilariae in various hollow organs and in the peritoneal cavity after treatment of Litomosoides carinii infected Mastomys natalensis with diethylcarbamazine and haloxon. Z Parasitenkd. 1983;69(3):387-92. PubMed PMID: 6880345.

18: Jortner BS, Pope AM, Heavner JE. Haloxon-induced delayed neurotoxicity: effect of plasma A (aryl) esterase activity on severity of lesions in sheep. Neurotoxicology. 1983 Summer;4(2):241-5. PubMed PMID: 6314214.

19: Hixson EJ. Consideration of dose levels for delayed neurotoxicity testing in hens: the relationship of neurotoxic dosages to acute LD50 values. Neurotoxicology. 1983 Spring;4(1):131-7. PubMed PMID: 6192368.

20: Wilson RD, Witzel DA, Verlander JM. Somatosensory-evoked response of ataxic Angora goats in suspected haloxon-delayed neurotoxicity. Am J Vet Res. 1982 Dec;43(12):2224-6. PubMed PMID: 7165170.